Abivax SA ADR (2X10)
XSTU 
Summary
2X10 Chart
Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts
Abivax Société Anonyme is advancing obefazimod for ulcerative colitis and Crohn's, with recent safety concerns now largely addressed. ABVX raised $920 million, extending its cash runway into Q4 2029 and strengthening its negotiating position for potential M&A. ABVX stock is fairly valued in the $90s, with upside contingent on a favorable UC label and positive Phase 2b CD data in 2027.
4 Biotech Stocks to Watch as Potential Takeover Targets
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Abivax SA ADR (2X10) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Abivax SA ADR ever had a stock split?
Abivax SA ADR Profile
| Biotechnology Industry | Healthcare Sector | Marc de Garidel CEO | XSTU Exchange | US00370M1036 ISIN |
| FR Country | 80 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ABIVAX Société Anonyme operates in the forefront of biotechnology with a focus on discovering and developing therapeutic solutions aimed at modulating the body's natural immune response. Founded in 2013 and with its headquarters in Paris, France, this clinical-stage company is dedicated to addressing chronic inflammatory diseases through innovative treatments. By leveraging the body's own regulatory mechanisms, ABIVAX aims to provide effective and potentially pioneering therapies for diseases that currently have limited treatment options.
Products and Services
- Obefazimod:
As the lead drug candidate of ABIVAX, obefazimod represents a significant advancement in the treatment of chronic inflammatory diseases. Currently, it is undergoing Phase 3 clinical trials for its efficacy against moderately to severely active ulcerative colitis in adults. This therapeutic approach underscores ABIVAX’s commitment to tackling unmet medical needs within the realm of inflammatory diseases through the utilization of the body's inherent mechanisms for restoring immune balance.
Contact Information
